A Phase II Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Conclusions Despite some evidence of efficacy in this setting, the primary endpoint for the study was not met. In the era of targeted agents that are well-tolerated, the combination of fludarabine and alemtuzumab should be used rarely for a select group of fit patients who are refractory to standard therapies. Teaser We evaluated alemtuzumab in combination with fludarabine for patients with relapsed CLL. Sixty patients were enrolled in this phase II study, and the complete response rate was 8.3% with an overall response rate of 28.3%. While many patients developed CMV reactivation, these episodes were manageable. This regimen may be considered for fit patients with multiply relapsed disease.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research